Delivery Order SPE2DB22D3016-SPE2DB24FBDE0

Award Date 8/6/24
Potential Completion Date 8/7/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $31,416.41 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to...
This is a $9,062.41 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The contract is for the delivery of 4565873440 REXULTI 1 MG tablet prescription medication. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 between AmerisourceBergen and DLA Troop Support Medical for providing a comprehensive range of pharmaceutical and medical supplies to...
This is a $1,959.96 firm fixed price delivery order awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of REXULTI 2 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of August 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of...
This is a $15,363.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of REXULTI 2 MG TABLET 30S, which is a prescription medication. The contract has an ultimate completion date of August 9, 2024. This award is a child contract under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at $999,999,999 and running...
This is a $9,056.98 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) Troop Support Medical. The order is for the pharmaceutical product REXULTI 1 MG TABLET 30S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract...
This is a $3,922.63 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract provides for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product, to support military healthcare programs. The contract has a period of performance through February 13, 2025 and is not designated as a set-aside. AmerisourceBergen is the prime contractor and holds a...
This is a $2,342.63 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is to deliver REXULTI 2 MG TABLET 30S, a mental health medication, with an ultimate completion date of April 13, 2023. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which...
This is a $15,267.20 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of REXULTI 3 MG TABLET 30S, a prescription medication, with a performance period running through January 22, 2025. The contract is not designated as a set-aside, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This is a delivery order awarded to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of REXULTI 2 MG TABLET 30S, a prescription medication. The contract has a ceiling value of $3,928.00 and a completion date of September 27, 2024. The contract is a firm-fixed-price delivery order with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,077.50, is for the delivery of REXULTI 2 MG TABLET 30S, a prescription medication. The contract has a completion date of January 15, 2025 and uses a firm fixed price pricing type. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB24FBDE0
    Delivery Order

This is a $15,157.99 firm-fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of REXULTI 2 MG TABLET 30S, a prescription medication. This delivery order is part of a larger indefinite delivery contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has no set-aside designation and is scheduled for completion by August 7, 2024.

Generated 11/5/24, 9:03 AM